SAB Biotherapeutics Inc.

0.03
0.00 (19.52%)
At close: Apr 07, 2025, 12:06 PM

SAB Biotherapeutics Statistics

Share Statistics

SAB Biotherapeutics has 9.29M shares outstanding. The number of shares has increased by -99.14% in one year.

Shares Outstanding 9.29M
Shares Change (YoY) -99.14%
Shares Change (QoQ) 0%
Owned by Institutions (%) 9.5%
Shares Floating 7.49M
Failed to Deliver (FTD) Shares 1.05K
FTD / Avg. Volume 4.56%

Short Selling Information

The latest short interest is 0, so 0% of the outstanding shares have been sold short.

Short Interest 0
Short % of Shares Out 0%
Short % of Float 0%
Short Ratio (days to cover) 0

Valuation Ratios

The PE ratio is -0.02 and the forward PE ratio is null. SAB Biotherapeutics's PEG ratio is 0.

PE Ratio -0.02
Forward PE n/a
PS Ratio 0.53
Forward PS 0.3
PB Ratio 0.03
P/FCF Ratio -0.02
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for SAB Biotherapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.98, with a Debt / Equity ratio of 0.18.

Current Ratio 2.98
Quick Ratio 2.98
Debt / Equity 0.18
Debt / EBITDA -0.11
Debt / FCF -0.14
Interest Coverage 134.77

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $23.2K
Profits Per Employee $-598.34K
Employee Count 57
Asset Turnover 0.03
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -0.34% in the last 52 weeks. The beta is 0.45, so SAB Biotherapeutics's price volatility has been higher than the market average.

Beta 0.45
52-Week Price Change -0.34%
50-Day Moving Average 0.05
200-Day Moving Average 0.05
Relative Strength Index (RSI) 41.79
Average Volume (20 Days) 23.07K

Income Statement

In the last 12 months, SAB Biotherapeutics had revenue of 1.32M and earned -34.11M in profits. Earnings per share was -3.68.

Revenue 1.32M
Gross Profit 1.32M
Operating Income -42.91M
Net Income -34.11M
EBITDA -42.91M
EBIT -34.42M
Earnings Per Share (EPS) -3.68
Full Income Statement

Balance Sheet

The company has 8.9M in cash and 4.67M in debt, giving a net cash position of 4.23M.

Cash & Cash Equivalents 8.9M
Total Debt 4.67M
Net Cash 4.23M
Retained Earnings -124.17M
Total Assets 44.2M
Working Capital 15.81M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -34.29M and capital expenditures 0, giving a free cash flow of -34.29M.

Operating Cash Flow -34.29M
Capital Expenditures 0
Free Cash Flow -34.29M
FCF Per Share -3.7
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -3244.87% and -2579.03%.

Gross Margin 100%
Operating Margin -3244.87%
Pretax Margin -2579.03%
Profit Margin -2579.03%
EBITDA Margin -3244.87%
EBIT Margin -3244.87%
FCF Margin -2593.15%

Dividends & Yields

SABSW does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

Currently there are no analyst rating for SABSW.

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Stock Forecasts

Scores

Altman Z-Score -6.03
Piotroski F-Score 1